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BACKGROUND: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients 
With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin 
reduced cardiovascular death or heart failure (HF) hospitalization and total HF 
hospitalizations, and slowed the progressive decline in kidney function in patients 
with HF and a reduced ejection fraction, with and without diabetes. We aim to 
study the effect of empagliflozin on cardiovascular and kidney outcomes across 
the spectrum of kidney function.
METHODS:  In this prespecified analysis, patients were categorized by the presence 
or absence of chronic kidney disease (CKD) at baseline (estimated glomerular 
filtration rate [eGFR] <60 ml/min/1.73 m2 or albumin-to-creatine ratio >300 mg/g). 
The primary and key secondary outcomes were: (1) a composite of cardiovascular 
death or HF hospitalization (primary outcome); (2) total HF hospitalizations; and (3) 
eGFR slope. The direct impact on kidney events was investigated by a prespecified 
composite kidney outcome (defined as a sustained profound decline in eGFR, chronic 
dialysis, or transplant). The median follow-up was 16 months.
RESULTS:  Of 3730 patients who were randomized to empagliflozin or placebo, 
1978 (53%) had CKD. Empagliflozin reduced the primary outcome and total 
HF hospitalizations in patients with and without CKD: hazard ratio (HR)=0.78 
(95% CI, 0.65–0.93) and HR=0.72 (95% CI, 0.58–0.90), respectively (interaction 
P=0.63). Empagliflozin slowed the slope of eGFR decline by 1.11 (0.23–1.98)  
ml/min/1.73 m2/yr in patients with CKD and by 2.41 (1.49–3.32) ml/min/1.73 m2/yr 
in patients without CKD. The risk of the composite kidney outcome was reduced 
similarly in patients with and without CKD: HR=0.53 (95% CI, 0.31–0.91) and 
HR=0.46 (95% CI, 0.22–0.99), respectively. The effect of empagliflozin on the 
primary composite outcome and key secondary outcomes was consistent across 
a broad range of baseline kidney function, measured by clinically relevant eGFR 
subgroups or by albuminuria, including patients with eGFR as low as 20 ml/
min/1.73 m2. Empagliflozin was well tolerated in CKD patients.
CONCLUSIONS: In EMPEROR-Reduced, empagliflozin had a beneficial effect 
on the key efficacy outcomes and slowed the rate of kidney function decline 
in patients with and without CKD, and regardless of the severity of kidney 
impairment at baseline.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT03057977.
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The incidence and prevalence of both heart failure (HF) and kidney disease are increasing.1 Patients with HF with reduced ejection fraction have a 
poor quality of life and a high risk of adverse cardiovas-
cular events and death, particularly in those with kidney 
impairment.2,3 Additionally, patients with chronic kidney 
disease (CKD) commonly develop heart failure, and the 
most common cause of demise is cardiovascular death.
For nearly 2 decades, both angiotensin converting 
enzyme inhibitors and angiotensin receptor blockers 
have been used for the treatment of both HF and re-
duced ejection fraction, as well as for the management 
of albuminuric CKD.4–7 In both conditions, initiation 
of treatment with these drugs is commonly accompa-
nied by mild transient worsening of kidney function 
attributable to their hemodynamic effects on the in-
traglomerular pressure in the kidneys. This early azo-
temia frequently leads clinicians to withhold or fail to 
up-titrate these drugs to achieve the target doses in 
HF with reduced ejection fraction, and may therefore 
deprive patients of the clinical benefit associated with 
their optimal use.8,9 More recently, sacubitril/valsartan 
was shown to slow the decline in estimated glomerular 
filtration rate (eGFR) in patients with both a reduced 
and preserved ejection fraction.10,11
Sodium glucose contransporter-2 (SGLT2) inhibitors 
have been shown to reduce eGFR decline, progression 
of kidney disease, or kidney failure (including renal 
death, the need for dialysis, or kidney transplantation), 
as well as the risk of HF hospitalizations and cardio-
vascular death in patients with type 2 diabetes.12–17 In 
patients with type 2 diabetes and albuminuric CKD en-
rolled in the CREDENCE trial (Canagliflozin and Renal 
Outcomes in Type 2 Diabetes and Nephropathy), cana-
gliflozin reduced the risk of kidney failure and serious 
cardiovascular events compared with placebo.17 Most 
recently, in the DAPA-CKD trial (A Study to Evaluate the 
Effect of Dapagliflozin on Renal Outcomes and Cardio-
vascular Mortality in patients with Chronic Kidney Dis-
ease), which enrolled patients with albuminuric kidney 
disease with or without diabetes, dapagliflozin reduced 
the rate of serious kidney outcomes, hospitalizations 
for HF, and mortality.18
In EMPEROR-Reduced (Empagliflozin Outcome Trial 
in Patients with Chronic Heart Failure with Reduced 
Ejection Fraction), empagliflozin reduced the composite 
of cardiovascular death or HF hospitalization and first 
and recurrent hospitalizations for HF, slowed the pro-
gressive decline in kidney function, and reduced the risk 
of serious kidney events in patients with and without 
diabetes.19 Importantly, in EMPEROR-Reduced, patients 
were eligible for enrollment with an eGFR as low as 20 
ml/min/1.73 m2 and more than half of the patients had 
prevalent CKD at baseline. Thus, the trial afforded the 
opportunity of investigating the efficacy and safety of 
empagliflozin on cardiac and kidney outcomes accord-
ing to CKD and across a wide range of kidney function; 
these findings were a prespecified analysis of EMPER-
OR-Reduced.
METHODS
Study Rationale, End Points, and 
Randomization Procedures
The rationale and design of EMPEROR-Reduced have been 
previously published.20 In short, EMPEROR-Reduced is a dou-
ble-blind, placebo-controlled, parallel-group, event-driven 
randomized trial that randomly assigned 3730 patients with 
class II, III, or IV HF and an ejection fraction of ≤40% to 
receive either empagliflozin (10 mg once daily) or placebo, in 
addition to recommended heart failure therapy.
The primary outcome and the first 2 secondary outcomes 
were evaluated using a hierarchical testing procedure. The 
primary outcome was a composite of adjudicated cardiovas-
cular death or hospitalization for heart failure, analyzed as the 
time to the first event. The first secondary outcome was the 
occurrence of all adjudicated hospitalizations for heart failure, 
including first and recurrent events. The second secondary 
outcome was the rate of the decline in eGFR during double-
blind treatment. A composite kidney outcome (see Kidney 
Endpoint Definition section), mortality from cardiovascular 
causes and all-cause death were also prespecified outcomes, 
but were not part of the testing hierarchy.
Randomization was stratified according to geographical 
region (North America, Latin America, Europe, Asia, or other), 
diabetes status at screening, and eGFR at screening (<60 
or ≥60 ml/min/1.73 m2), according to the Chronic Kidney 
Disease Epidemiology Collaboration equation. The median 
follow-up duration was 16 months.
Clinical Perspective
What Is New?
• The effect of empagliflozin in patients with heart 
failure with reduced ejection fraction with or with-
out chronic kidney disease has not been previously 
reported.
• The authors studied the effect of empagliflozin 
on cardiovascular and kidney outcomes across the 
entire spectrum of kidney function.
What Are the Clinical Implications?
• Empagliflozin reduced the primary outcome of 
death from cardiovascular causes or hospitalization 
for heart failure, first and repeated heart failure 
hospitalizations, and serious kidney outcomes in 
patients with and without chronic kidney disease.
• This study supports the use of empagliflozin 
for improving the outcomes of patients with 
heart failure with reduced ejection fraction and 
chronic kidney disease, even in those with an esti-
mated glomerular filtration rate as low as 20 mL/
(min·1.73 m2).
Zannad et al Benefits of Empagliflozin Across Kidney Function














Ethics approval was obtained at each study site, and 
all patients provided informed consent to participate in 
the study; the registration identifier at ClinicalTrials.gov is 
NCT03057977 (URL: https://www.clinicaltrials.gov; Unique 
identifier: NCT03057977).
Baseline Categorization of Kidney 
Impairment
For this prespecified subgroup analyses, patients were cat-
egorized by the presence or absence of CKD at baseline. We 
defined prevalent CKD by the presence of an eGFR <60 ml/
min/1.73 m2 or urine albumin-to-creatine ratio (UACR) >300 
mg/g, and no CKD was defined by an eGFR ≥60 ml/min/1.73 
m2 and UACR ≤300 mg/g. We evaluated the influence in 
clinically relevant categories of: (1) presence or absence of 
CKD; (2) 5 baseline eGFR categories (<30, 30–44, 45–59, 
60–89, and ≥90 ml/min/1.73 m2); and (3) 3 baseline UACR 
categories (<30, 30–300, and >300 mg/g) on all 3 of the 
hierarchically-ranked outcomes and on several  cardio-kid-
ney outcomes.
Kidney End Point Definition
The composite kidney outcome was defined as time to first 
occurrence of chronic dialysis, kidney transplant, sustained 
reduction of ≥40% eGFR, or sustained eGFR <15 ml/min/1.73 
m2 if eGFR was >30 ml/min/1.73 m2 or <10 ml/min/1.73 m2 
for patients with baseline eGFR ≤30 ml/min/1.73 m2.
Anemia
The analysis of anemia included all patients with available 
values at baseline and at least 1 on-treatment measurement. 
Anemia was defined by the lower limit of normal given by the 
central laboratory depended on sex and age.
Statistical Analyses
Patient characteristics and adverse events were analyzed 
descriptively. Time-to-first-event analyses were performed 
with a Cox proportional hazards model, and adjusted for 
age, sex, region, diabetes status, and ejection fraction at 
baseline. These analyses were performed according to the 
intention-to-treat principle for all randomized patients, and 
included data up to the end of the planned treatment period. 
Total (first and recurrent) hospitalizations for HF were evalu-
ated accordingly with a joint frailty model that accounted 
for cardiovascular death. As prespecified, the slope of eGFR 
decline was analyzed based on on-treatment data (base-
line and other off-treatment data were not included in the 
model) by a random coefficient model allowing for random 
intercept and random slope per patient. Continuous end 
points were analyzed in a mixed model with repeated mea-
sures. An analysis of covariance was used to compare eGFR 
baseline and eGFR 30 days after treatment discontinuation 
in the 2 treatment groups. The analysis of covariance, joint 
frailty, slope, and mixed model with repeated measures 
models all included the same covariates as the Cox model. 
To assess the consistency of effects across subgroups, sub-
group-by-treatment interaction terms were added to the 
models. Adverse event analyses were based on patients 
with events occurring during the on-treatment period. SAS 
Version 9.4 was used for all analyses.
Data Sharing Statement
Data will be made available on request in adherence with 
transparency conventions in medical research and through 
requests to the corresponding author. The executive com-
mittee of EMPEROR-Reduced has developed a compre-
hensive analysis plan and numerous prespecified analyses, 
which will be presented in future scientific meetings and 
publications. At a later time point, the full database will be 
made available in adherence with the transparency policy of 




Among the 3730 patients included in the trial, 1978 
(53%) had prevalent CKD at baseline. Compared with 
patients without CKD, those with CKD were older (70 
versus 63 years), had a longer duration of HF (mean 
time since diagnosis, 6.8 versus 5.5 years), were more 
likely to have diabetes (54% versus 45%), and were 
less likely to be treated with angiotensin converting en-
zyme inhibitors or angiotensin receptor blockers (67% 
versus 73%). Reflective of the subgroup definition for 
prevalent CKD, eGFR was much lower for patients with 
CKD (mean, 47 versus 79 ml/min/1.73 m2), and the 
UACR was much higher (median, 36 versus 15 mg/g). 
The baseline characteristics in the placebo and empa-
gliflozin groups were well balanced in patients with 
and without CKD (Table 1). The patient characteristics 
across the 5 eGFR categories follow the same pattern as 
previously described and are presented in Table I of the 
Data Supplement. The use of angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers and 
mineralocorticoid receptor antagonists less frequent in 
patients with lower eGFR at baseline. Patient charac-
teristics across the 3 UACR categories are presented in 
Table II of the Data Supplement.
Event Rates of Patients With and 
Without Kidney Impairment
Patients with prevalent CKD had a higher rate of 
the primary composite outcome, first and recurrent 
hospitalizations for HF, composite kidney outcome, 
all-cause hospitalizations, and cardiovascular and all-
cause death (Table 2).
Primary and Key Secondary End Points
Empagliflozin reduced the primary outcome of time-
to-first–cardiovascular death or HF hospitalization in 
patients with and without prevalent CKD (HR, 0.78; 
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Age, y 63.7±11.2 62.3±11.3 70.4±9.5 70.1±9.8
Female sex 204 (23.2) 183 (21.1) 232 (23.6) 273 (27.4)
Race
  White 580 (66.0) 580 (66.9) 742 (75.6) 721 (72.3)
  Black 73 (8.3) 69 (8.0) 50 (5.1) 65 (6.5)
  Asian 185 (21.0) 181 (20.9) 152 (15.5) 154 (15.4)
  Other 27 (3.1) 29 (3.3) 24 (2.4) 34 (3.4)
  Missing 14 (1.6) 8 (0.9) 13 (1.3) 23 (2.3)
Region
  North America 94 (10.7) 78 (9.0) 118 (12.0) 135 (13.5)
  Latin America 325 (37.0) 333 (38.4) 316 (32.2) 310 (31.1)
  Europe 276 (31.4) 277 (31.9) 397 (40.5) 399 (40.0)
  Asia 134 (15.2) 129 (14.9) 114 (11.6) 116 (11.6)
  Other 50 (5.7) 50 (5.8) 36 (3.7) 37 (3.7)
Time since diagnosis of heart failure, y 5.2±5.6 5.7±6.3 6.7±6.4 6.8±6.6
NYHA functional classification
  II 683 (77.7) 671 (77.4) 713 (72.7) 728 (73.0)
  III 193 (22.0) 192 (22.1) 262 (26.7) 262 (26.3)
  IV 3 (0.3) 4 (0.5) 6 (0.6) 7 (0.7)
BMI, kg/m2 27.86±5.47 27.64±5.49 28.08±5.44 27.91±5.19
Heart rate, beats/min 71.9±11.9 71.8±12.1 70.2±11.5 71.3±11.5
Systolic blood pressure, mm Hg 122.4±15.5 120.1±14.9 122.8±16.3 122.4±15.6
Diastolic blood pressure, mm Hg 74.7±10.6 74.3±10.3 73.4±11.2 73.3±10.9
LVEF, % 27.4±6.0 26.8±6.0 28.0±5.9 27.5±6.2
NT-proBNP, pg/mL (median [IQR]) 1505 (907–2511) 1548 (914–2650) 2339 (1370–4343) 2329 (1417–4415)
Principal cause of heart failure
  Ischemic 433 (49.3) 416 (48.0) 548 (55.9) 528 (53.0)
Medical history
  HHF in last 12 mo 262 (29.8) 271 (31.3) 315 (32.1) 303 (30.4)
  Atrial fibrillation* 244 (27.8) 261 (30.1) 420 (42.8) 444 (44.5)
  Hypertension 575 (65.4) 578 (66.7) 774 (78.9) 769 (77.1)
  Diabetes 402 (45.7) 384 (44.3) 523 (53.3) 542 (54.4)
eGFR (CKD-EPI), mL/(min·1.73 m2) 79.0±13.8 79.1±14.0 46.5±15.0 47.4±15.1
eGFR (CKD-EPI) <60 mL/(min·1.73 m2) 0 0 893 (91.0) 906 (90.9)
UACR, mg/g, median (IQR) 15 (6, 44) 16 (6, 43) 36 (11, 194) 36 (11, 160)
Device therapy
  Implantable cardioverter-defibrillator† 229 (26.1) 236 (27.2) 348 (35.5) 357 (35.8)
  Cardiac resynchronization therapy‡ 55 (6.3) 69 (8.0) 165 (16.8) 153 (15.3)
Heart failure medication
  ACE inhibitor 447 (50.9) 440 (50.7) 420 (42.8) 395 (39.6)
  ARB§ 207 (23.5) 194 (22.4) 244 (24.9) 261 (26.2)
  ARNI 166 (18.9) 161 (18.6) 172 (17.5) 225 (22.6)
  Diuretics§§ 722 (82.1) 732 (84.4) 887 (90.4) 903 (90.6)
  MRA 648 (73.7) 665 (76.7) 656 (66.9) 687 (68.9)
(Continued )
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95% CI, 0.65–0.93 [with]; HR, 0.72; 95% CI, 0.58–
0.90 [without]; interaction P=0.63). Empagliflozin also 
reduced the key secondary endpoint of first and recur-
rent HF hospitalizations in patients with and without 
prevalent CKD (interaction P=0.78) (Figure 1).
Empagliflozin reduced the slope of decline in eGFR 
by 1.11 (0.23–1.98) ml/min/1.73 m2 per year in pa-
tients with CKD and by 2.41 (1.49–3.32) ml/min/1.73 
m2 per year in patients without CKD (interaction 
P=0.045) (Table 3). The change of eGFR over time for 
patients with and without CKD is shown in Figure 2. 
An early eGFR decrease (“dip”) was observed in the 
empagliflozin-treated group. At week 4, the placebo-
corrected eGFR dip between the treatment groups 
was similar (2.4 ml/min/1.73 m2 for patients with CKD 
and 2.7 ml/min/1.73 m2 without CKD; interaction 
P=0.59). Thereafter, stabilization and recovery toward 
baseline was observed in the empagliflozin group, 
whereas eGFR declined progressively in the placebo 
group.
In a subset of 966 patients (484 with and 482 with-
out CKD) that had measurements of eGFR at baseline 
and at 23 to 45 days after the discontinuation of treat-
ment, empagliflozin reduced the decline in eGFR dur-
ing the course of the trial by 3.0 (95% CI, 1.0–5.1) ml/
min/1.73 m2 in patients with CKD and by 3.9 (95% CI, 
1.8–6.0) ml/min/1.73 m2 in patients without CKD (in-
teraction P=0.56) (Table 4).
  Beta blocker 834 (94.9) 820 (94.6) 929 (94.7) 946 (94.9)
  Cardiac glycosides 139 (15.8) 161 (18.6) 144 (14.7) 150 (15.0)
  Nitrates 85 (9.7) 108 (12.5) 155 (15.8) 147 (14.7)
  Ivabradine 63 (7.2) 67 (7.7) 71 (7.2) 58 (5.8)
  Hydralazine 17 (1.9) 24 (2.8) 44 (4.5) 41 (4.1)
Other medication
  Lipid-lowering drugs 595 (67.7) 560 (64.6) 714 (72.8) 741 (74.3)
  Antithrombotic drugs 679 (72.2) 664 (76.6) 857 (87.4) 863 (86.6)
Data are n (%) or mean±SD for randomized patients, unless otherwise stated. ACEi indicates angiotensin-converting enzyme inhibitor; 
ARB, angiotensin-receptor blocker; ARNI, angiotensin-receptor neprilysin inhibitor; BMI, body mass index; CKD, chronic kidney disease; CKD-
EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart 
failure; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; and UACR, urine albumin-to-creatinine ratio. 
*Atrial fibrillation reported in any ECG before treatment intake or history of atrial fibrillation reported as medical history. 
†Implantable cardioverter defibrillator with or without cardiac resynchronization therapy. 
‡Cardiac resynchronization therapy with or without a defibrillator. 
§Excluding valsartan when taken with sacubitril because sacubitril/valsartan is shown as ARNI. 












Table 2. Event rates by CKD Status
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Adjudicated HHF or CV 
death
142 (16.2) 13.0 219 (22.3) 18.4 187 (21.6) 18.0 273 (27.4) 23.6
First and recurrent HHF 
(number of events)
143 - 245 - 203 - 349 -
Composite kidney end 
point*
10 (1.1) 1.1 20 (2.0) 2.0 20 (2.3) 2.3 38 (3.8) 3.8
All-cause hospitalization 266 (30.3) 28.1 422 (43.0) 42.9 330 (38.1) 37.7 464 (46.5) 49.5
Cardiovascular death 81 (9.2) 6.9 106 (10.8) 8.2 79 (9.1) 6.8 121 (12.1) 9.1
All-cause mortality 96 (10.9) 8.2 153 (15.6) 11.8 96 (11.1) 8.3 168 (16.9) 12.7
Data for randomized patients. CKD indicates chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; CV, cardiovascular; 
eGFR, estimated glomerular filtration rate (ml/min/1.73 m2 by CKD-EPI); HHF, hospitalization for heart failure; and UACR, urinary albumin-to-creatinine ratio (mg/g). 
*Composite exploratory end point included chronic dialysis or kidney transplant or sustained reduction of ≥40% in eGFR or sustained eGFR <15 (for patients with 
baseline eGFR ≥30) or sustained eGFR <10 (for patients with baseline eGFR <30).
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The effect of empagliflozin on the primary compos-
ite outcome and the key secondary outcomes across 
the 5 eGFR categories, including patients with an eGFR 
between 20 and 30 ml/min/1.73 m2, and 3 UACR cate-
gories is shown in Figure 1 and Table 3. Baseline kidney 
function did not influence the benefits of empagliflozin 
on the primary endpoint or on total hospitalizations 
for HF, but baseline eGFR had a modest effect on the 
magnitude of the absolute treatment difference on the 
eGFR slope (interaction P=0.033).
Other Prespecified Outcomes
The exploratory composite kidney outcome of sus-
tained profound decline in eGFR, chronic dialysis, or 
kidney transplant was reduced similarly in patients with 
and without CKD (HR, 0.53; 95% CI, 0.31–0.91 in pa-
tients with CKD; HR, 0.46; 95% CI, 0.22–0.99 in pa-
tients without CKD; interaction P=0.78). The absolute 
differences of event rates between placebo and empa-
gliflozin were 1.17 per 100 patient-years for patients 
without CKD and 1.78 per 100 patient-years for pa-
tients with CKD (Figure 1).
When baseline eGFR was analyzed by 5 subgroups, 
kidney function did not influence the magnitude of the 
effect of the drug on the risk of the composite kidney 
outcome (interaction P=0.74). Investigator reported 
acute kidney injury was less frequent in the empa-
gliflozin group, both in patients with CKD and without 
CKD (HR, 0.73; 95% CI, 0.47–1.15 [with]; HR, 0.56; 
95% CI, 0.28–1.11 [without]; interaction P=0.53). Fur-
thermore, baseline kidney function did not influence 
the effect of empagliflozin on all-cause hospitalizations 
or cardiovascular or all-cause mortality (Figure 3).
Empagliflozin reduced the risk of the composite 
outcome of the composite kidney endpoint or all-
cause mortality in patients with CKD (HR, 0.84; 95% 
CI, 0.68–1.03) and without CKD (HR, 0.87; 95% CI, 
0.67–1.14) (interaction P=0.80) (Figure 3).
Empagliflozin increased hemoglobin levels versus pla-
cebo, both in patients with and without prevalent CKD. 
Adjusted mean increases from baseline at week 52 were 
Figure 1. Clinical outcomes in patients by CKD status, eGFR and UACR categories at baseline.
Data for randomized patients; HR and 95% CI from Cox proportional hazards model unless otherwise noted. CKD-EPI indicates Chronic Kidney Disease Epidemiol-
ogy  Collaboration equation; CV, cardiovascular; eGFR, estimated glomerular filtration rate (CKD-EPI; ml/min/1.73 m2); HHF, hospitalization for heart failure; HR, 
hazard ratio; and UACR, urinary albumin-to-creatinine ratio (mg/g). *Prevalent CKD defined as eGFR (CKD-EPI) <60 ml/min/1.73 m2 or UACR >300 mg/g. †Evaluated 
using a joint frailty model together with CV death. ‡Composite exploratory endpoint included chronic dialysis or kidney transplant or sustained reduction of ≥40% 
in eGFR or sustained eGFR (CKD-EPI) <15 ml/min/1.73 m2 (for patients with baseline eGFR ≥30) or sustained eGFR <10 (for patients with baseline eGFR <30). §Not 
calculated as less than 14 events in this subgroup. **P value for interaction shown for CKD subgroups; P value for trend test shown for eGFR and UACR subgroups.
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0.67 g/dL (95% CI, 0.55–0.80) in patients with CKD and 
0.75 g/dL (95% CI, 0.62–0.88) in patients without CKD 
(interaction P=0.42). Of the 1905 patients with preva-
lent CKD, 535 (28%) had anemia at baseline. Empa-
gliflozin reduced the proportion of patients with ane-
mia; anemia persisted to last value on treatment in 71% 
(184 of 259) patients in the placebo group and in 50% 
(138 of 276) of patients in the empagliflozin group.
Adverse Events
Adverse events (AEs) by baseline CKD status and across 
the 5 eGFR categories were generally consistent with 
the AE profile in the overall population. As expected, 
the incidence of AE rates (including serious AEs and AEs 
leading to discontinuation of trial drug) was higher in 
patients with prevalent CKD at baseline and in patients 
with lower eGFR ranges. Generally, empagliflozin and 
placebo groups showed similar frequencies of the listed 
AEs across these subgroups (Table 5).
DISCUSSION
EMPEROR-Reduced enrolled a substantial proportion of 
patients with prevalent CKD and allowed patients to be 
included with an eGFR as low as 20 ml/min/1.73 m2. 
The current study demonstrates the favorable effects 
of empagliflozin on the primary efficacy outcome of 
time-to-first–cardiovascular death or HF hospitalization 
and the key secondary end points of total HF hospital-
izations and eGFR slope, as well as a reduction in seri-
ous kidney outcomes in patients with and without CKD 
and across the spectrum of kidney function, irrespective 
of degree of kidney injury measured by eGFR or albu-
minuria. Empagliflozin was well-tolerated in patients 
with severely impaired kidney function.
In patients with diabetes and increased cardiovascu-
lar risk, SGLT2 inhibitors have reduced the risk of car-
diovascular death and hospitalizations for HF, including 
in patients with baseline CKD.21,22 The findings of EM-
PEROR-Reduced along with those of DAPA-HF (Dapa-
gliflozin and Adverse Events in Chronic Heart Failure 
and a Reduced Ejection Fraction) extend these findings 
to patients with HF and a reduced ejection fraction, 
with or without diabetes.16,19,23 Patients in DAPA-HF 
had a higher baseline eGFR than those in EMPEROR-
Reduced (66 versus 62 ml/min/1.73 m2); the proportion 
of patients with CKD at baseline was higher in EMPER-
OR-Reduced. In DAPA-HF, dapagliflozin reduced the pri-
mary outcome of cardiovascular death or worsening HF 
leading to hospitalization or an urgent care visit simi-
larly in patients with or without CKD. These findings 
are highly concordant with the findings of EMPEROR-
Reduced reported herein.
In addition to their benefits on heart failure hospital-
izations, SGLT2 inhibitors also slow the progression of 
Table 3. eGFR Slope Analyses by CKD Status, eGFR, and UACR Categories at Baseline
Slope of change in eGFR per 
year*, mean±SE Empagliflozin Placebo
Absolute difference 
(95% CI) P Value
P value for 
interaction
All patients (N=3726) −0.55±0.23 –2.28±0.23 1.73 (1.10–2.37) <0.001  
By prevalent CKD status†
  No prevalent CKD (n=1744) −0.93±0.33 −3.33±0.33 2.41 (1.49–3.32) <0.001 0.045
  Prevalent CKD (n=1976) −0.22±0.32 −1.33±0.32 1.11 (0.23–1.98) 0.013
By eGFR (CKD-EPI) category, mL/(min·1.73 m2) P Value for 
trend
  ≥90 (n=449) −2.20±0.63 −4.17±0.66 1.96 (0.16–3.76) 0.033 0.033
  60 to <90 (n=1478) −0.72±0.36 −3.21±0.36 2.49 (1.49–3.49) <0.001
  45 to <60 (n=900) 0.03±0.47 −1.59±0.45 1.62 (0.35–2.89) 0.013
  30 to <45 (n=693) 0.05±0.54 −0.38±0.54 0.43 (–1.06 to 1.93) 0.57
  <30 (n=204) −0.17±0.92 −0.80±1.18 0.63 (–2.31 to  3.56) 0.68
By UACR category, mg/g P Value for 
trend
  Normoalbuminuria (<30) 
(n=2076)
−0.04±0.30 −2.13±0.31 2.09 (1.24–2.93) <0.001 0.29
  Microalbuminuria (30 to 
<=300) (n=1235)
−1.12±0.40 −2.35±0.40 1.23 (0.14–2.33) 0.028
  Macroalbuminuria (>300) 
(n=396)
−1.47±0.71 −2.87±0.72 1.40 (−0.58 to 3.37) 0.166
CKD indicates chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated 
glomerular filtration rate; and UACR, urinary albumin-to-creatinine ratio (mg/g).
*Data for the treated set of patients from random coefficient model; intercept and slope allowed to vary randomly between patients.
†Prevalent CKD defined as eGFR (CKD-EPI) <60 ml/min/1.73 m2 or UACR >300 mg/g. 
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chronic kidney disease, as reflected by a decrease in the 
rate of decline in eGFR over time and a reduction in the 
risk of end-stage kidney disease. In EMPEROR-Reduced, 
empagliflozin reduced the risk of the composite kidney 
endpoint by 50%, and this risk reduction was statistically 
significant, both in patients with and without CKD. Of 
note, the effect of dapagliflozin on a composite of serious 
kidney events was not statistically significant (HR 0.71; 
95% CI, 0.44–1.16), but this estimate was based on com-
paratively few events. It seems highly unlikely that dapa-
gliflozin does not have a kidney benefit similar to empa-
gliflozin, since dapagliflozin reduced the risk of end-stage 
kidney disease in the DAPA-CKD trial, which enrolled pa-
tients with albuminuric CKD who did not have HF (DAPA-
CKD enrolled patients with a baseline eGFR as low as 25 
ml/min/1.73 m2, whereas EMPEROR-Reduced allowed 
the participation of patients with a baseline eGFR as low 
as 20 ml/min/1.73 m2). Consequently, the patients with 
CKD in EMPEROR-Reduced had a baseline eGFR similar to 
those enrolled in DAPA-CKD (47 and 43 ml/min/1.73 m2, 
respectively), and lower than the mean eGFR of patients 
with type 2 diabetes and albuminuric CKD enrolled in 
the CREDENCE trial (56 ml/min/1.73 m2).17,18 Accordingly, 
when the results of DAPA-HF and EMPEROR-Reduced are 
combined in a meta-analysis, SGLT2 inhibition with these 
drugs reduced the risk of major kidney outcomes by 38% 
(HR, 0.62; 95% CI, 0.43–0.90) without evidence for het-
erogeneity.20
Kidney function declines progressively during the 
course of chronic heart failure.24,25 We showed a 
Figure 2. eGFR over time by CKD status at baseline.
Data for treated patients from a mixed model for repeated measures based on on-treatment data. Prevalent CKD defined as eGFR (CKD-EPI) <60 ml/min/1.73 m2 
or UACR >300 mg/g. CKD indicates chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular 
filtration rate; and UACR, urinary albumin-to-creatinine ratio. 
Table 4. Change of eGFR from Baseline to 30 Days After Treatment Discontinuation by CKD Status at Baseline
Total change in eGFR from 
baseline to follow-up, mL/
(min·1.73 m2) (mean±SE) Empagliflozin Placebo
Absolute 
difference 
(95% CI) P value
P value for 
interaction
All patients (N=966) −0.9 (0.5) −4.2 (0.5) 3.3 (1.8, 4.8) <0.001  
By prevalent CKD status*
  No prevalent CKD (n=482) −3.2 (0.7) −7.2 (0.8) 3.9 (1.8, 6.0) <0.001 0.56
  Prevalent CKD (n=484) 1.5 (0.8) −1.5 (0.7) 3.0 (1.0, 5.1) 0.004
CKD indicates chronic kidney disease; and eGFR, estimated glomerular filtration rate.
*Data for the treated set of patients from random coefficient model; intercept and slope allowed to vary randomly between 
patients.
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favorable effect of empagliflozin on kidney function us-
ing 3 metrics, ie, slowing of the slope of eGFR over time, 
attenuation of the decline in eGFR from baseline to the 
off-treatment assessment at the end of the trial, and a 
composite of serious kidney events. We noted a nomi-
nally significant treatment-by–baseline eGFR interaction 
for the effect of empagliflozin on the eGFR slope, which 
was apparent irrespective of whether the analysis cat-
egorized patients into 2 or 5 eGFR subgroups. However, 
these analyses are model-dependent and are based on 
absolute differences. Given the lower baseline values for 
eGFR in patients with CKD, the magnitude of benefit 
on eGFR slope with empagliflozin was proportionally 
similar in patients with and without CKD; furthermore, 
absolute declines in eGFR are likely to be more clinically 
meaningful in patients with CKD, since they accelerate 
the loss of eGFR to levels that are indicative of end-stage 
kidney disease. The importance of the effect of empa-
gliflozin on the course of kidney disease in patients with 
CKD is highlighted by the fact that, when compared 
with patients without CKD, patients with compromised 
eGFR experienced similar benefits of empagliflozin to 
prevent the decline in eGFR. The analyses that compared 
effects between off-treatment values at baseline and af-
ter treatment discontinuation were unconfounded by 
the presence of the study medication and show that 
empagliflozin protected the kidney regardless of CKD 
status. Additionally, both subgroups experienced similar 
reductions in the risk of the composite kidney outcome.
Potential mechanisms for the kidney benefits 
of SGLT2 inhibition include a reduction in single 
nephron hyperfiltration, decreased tubulointerstitial 
damage, suppression of hyperglycemia-induced pro-
duction of reactive oxygen species and angiotensin-
ogen, reduction of mitochondrial damage, and en-
hanced nutrient deprivation signaling.26–29 The latter 
mechanism may explain why empagliflozin increased 
hemoglobin and reduced the proportion of patients 
with anemia, irrespective of presence or absence of 
CKD at baseline.30
Despite an expected higher rate of adverse events in 
patients with CKD, there were no excess adverse events 
in patients receiving empagliflozin, as compared to pa-
tients receiving placebo, across all categories of kidney 
function. The initial dip in eGFR seen more commonly in 
empagliflozin-treated patients was not associated with 
an excess risk of investigator-reported acute kidney 
injury, regardless of the presence or absence of CKD. 
The rapid increase in eGFR seen when empagliflozin 
was withdrawn at the end of the trial indicates that 
the initial dip in eGFR represents a reversible functional 
change in intrarenal hemodynamics, which is seen in 
patients with and without CKD. This initial decline in 
eGFR did not prevent empagliflozin from exerting its 
long-term beneficial effects on heart failure events or 
on kidney function.
Limitations
Several limitations should be highlighted in this study. 
Although this was a prespecified secondary analysis, 
EMPEROR-Reduced was not powered to assess the 
Figure 3. Additional clinical outcomes by CKD status at baseline.
Data for randomized patients; HR and 95% CI from Cox proportional hazards model. CKD indicates chronic kidney disease; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration equation; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; HR, hazard ratio; Med-
DRA, Medical Dictionary for Regulatory Activities; and UACR, urinary albumin-to-creatinine ratio. *Prevalent CKD defined as eGFR (CKD-EPI) <60 ml/min/1.73 m2 
or UACR >300 mg/g. †Composite exploratory endpoint included chronic dialysis or kidney transplant or sustained reduction of ≥40% in eGFR or sustained eGFR 
(CKD-EPI) <15 ml/min/1.73 m2 (for patients with baseline eGFR ≥30) or sustained eGFR <10 (for patients with baseline eGFR <30). ‡Acute kidney injury based on 
MedDRA preferred term based on investigator-reported adverse events.
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effect of empagliflozin in subgroups such as CKD, 
much less to assess the effect in smaller subgroups 
such as the 5 categories of eGFR and 3 UACR catego-
ries. Although the benefits on the composite kidney 
outcome were based on relatively few events, as re-
flected in the confidence intervals, the point estimate 
of the magnitude of our findings of a benefit on kid-
ney outcomes is very similar to that seen in large-
scale trials of patients with diabetes or with chronic 
kidney disease.
Conclusions
In EMPEROR-Reduced, empagliflozin reduced the key 
efficacy outcomes of time-to-first–HF hospitalization 
or cardiovascular death and first and recurrent HF 
hospitalizations, and slowed the rate of kidney func-
tion decline, in patients with and without CKD and 
across a broad kidney function spectrum. Moreover, 
in patients with and without CKD, empagliflozin re-
duced a kidney composite outcome that incorporated 
clinically meaningful and sustained deterioration in 
kidney function, chronic dialysis, and kidney trans-
plant; treatment with the drug reduced the proportion 
of CKD patients with anemia. These efficacy benefits 
and the consistent safety profile with the overall trial 
population support the clinical use of empagliflozin in 
patients with HF with reduced ejection fraction across 
the broad spectrum of kidney function, including 
those with severe kidney function impairment down 
to an eGFR of 20 ml/min/1.73 m2 and irrespective of 
the degree of albuminuria.




Rate per 100 
patient-years n/N (%)
Rate per 100 
patient-years
Any AE
  No prevalent CKD 632/879 (71.9) 130.7 636/865 (73.5) 140.9
  Prevalent CKD 787/981 (80.2) 168.7 825/995 (82.9) 193.7
Serious AE
  No prevalent CKD 310/879 (35.3) 35.6 381/865 (44.0) 48.6
  Prevalent CKD 462/981 (47.1) 52.1 513/995 (51.6) 61.2
AE leading to discontinuation of trial drug
  No prevalent CKD 124/879 (14.1) 11.5 116/865 (13.4) 11.0
  Prevalent CKD 198/981 (20.2) 16.9 210/995 (21.1) 17.8
Acute renal failure*
  No prevalent CKD 52/879 (5.9) 5.0 62/865 (7.2) 6.1
  Prevalent CKD 123/981 (12.5) 11.2 130/995 (13.1) 11.7
Volume depletion
  No prevalent CKD 81/879 (9.2) 7.9 74/865 (8.6) 7.4
  Prevalent CKD 116/981 (11.8) 10.5 110/995 (11.1) 10.1
Urinary tract infection
  No prevalent CKD 32/879 (3.6) 3.0 30/865 (3.5) 2.9
  Prevalent CKD 58/981 (5.9) 5.1 53/995 (5.3) 4.6
Bone fracture
  No prevalent CKD 15/879 (1.7) 1.4 13/865 (1.5) 1.2
  Prevalent CKD 30/981 (3.1) 2.6 29/995 (2.9) 2.5
Confirmed hypoglycemia†
  No prevalent CKD 11/879 (1.3) 1.0 9/865 (1.0) 0.9
  Prevalent CKD 16/981 (1.6) 1.4 19/995 (1.9) 1.6
Genital infection
  No prevalent CKD 15/879 (1.7) 1.4 7/865 (0.8) 0.7
  Prevalent CKD 16/981 (1.6) 1.4 5/995 (0.5) 0.4
Data are AEs in the treated set of patients classified using Medical Dictionary for Regulatory Activities version 23.0. AE 
indicates adverse event; and CKD, chronic kidney disease. 
*Narrow standardized MedDRA query “acute renal failure” from MedDRA version 23. 
†Plasma glucose ≤70 mg/dL or requiring assistance.
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